Biointron is excited to announce our participation in World ADC USA 2025, a leading event dedicated to accelerating the development of antibody-drug conjugates (ADCs). Taking place in San Diego, CA, from November 3-6, 2025, this conference brings together industry experts, researchers, and innovators to explore the latest advancements in ADC technology, clinical progress, and manufacturing solutions.

Biointron is excited to announce our participation in World ADC Asia 2025, set to take place in Incheon, South Korea, from June 10-12, 2025. This premier event is dedicated to accelerating the development of antibody-drug conjugates (ADCs), uniting experts from across the biopharmaceutical industry to share insights, showcase innovations, and drive forward the future of targeted therapeutics.

This January, top news includes glycoengineering, anti-malarial antibodies, and PROTACs.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

Antibody-drug conjugates (ADCs) have emerged as a transformative class of therapeutics, combining the specificity of monoclonal antibodies with the potent cytotoxic effects of small-molecule drugs. By targeting specific antigens on cancer cells, ADCs deliver highly potent payloads while sparing healthy tissues, reducing systemic toxicity, and improving therapeutic outcomes.

Biointron is excited to announce our participation in the World ADC London 2025 Conference, set to take place March 3-6, 2025, in London, UK.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads. This strategy allows for selective delivery of toxic agents to tumor cells while minimizing harm to healthy tissues.

Antibody-dependent cell-mediated cytotoxicity (ADCC) is an essential immune response where antibodies, primarily of the IgG1 class, engage immune cells to target and destroy cancer cells. By recognizing tumor cell antigens, monoclonal antibodies (mAbs) bridge immune effector cells, such as natural killer (NK) cells, with target cells to mediate cytotoxicity.

Antibody-drug conjugates (ADCs) combine the targeting capabilities of antibodies with the potent cytotoxicity of chemotherapy drugs, or “payloads.” By selectively delivering highly toxic drugs directly to tumor cells, ADCs aim to maximize efficacy while minimizing harm to healthy tissue. ADCs consist of three main components: a monoclonal antibody, a cytotoxic drug (payload), and a linker that connects the two. Each of these components can be engineered to improve ADC performance, including factors like specificity, stability, and controlled drug release.

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. The development of ADCs traces back over a century and mirrors advancements in molecular biology and biotechnology, resulting in several approved drugs used in oncology today.

Antibody-drug conjugates (ADCs) represent a promising approach in oncology due to their ability to deliver cytotoxic drugs selectively to cancer cells. By combining the tumor-targeting specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents, ADCs are engineered to improve therapeutic outcomes while minimizing damage to healthy tissue. However, their therapeutic efficacy is not only dependent on the specific antibody or drug payload but also on a critical parameter known as the drug–antibody ratio (DAR).

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) represent two major advances in the field of cancer immunotherapy. While both approaches have achieved notable successes, especially in targeting specific cancers, their individual limitations, such as restricted efficacy in certain tumor types and adverse side effects, present challenges. Combining these two therapies has emerged as a promising strategy to address these shortcomings.

For more than 30 years, antibody drug development has transformed the landscape of immunotherapy, treating various diseases from cancer to autoimmune diseases. The use of therapeutic monoclonal antibodies (mAbs) began after the groundbreaking development of the hybridoma technique by Kohler and Milstein in 1975, with further development into humanization approaches over the next decade.